




Candida pneumonia? An immediate post-mortem study 25 patients dying in ICU after >72hrs' stay Excluded, anyone under immunosuppression, with hematologic malignancy, with ANC <1000


- Upon death, set FiO2 100%, then:
- ETT aspirate via mucus trap/collector
- Bronchoscopy through each lung (different scope for each lung) with PSB sampling
- As above, with BAL
- Lung biopsies through thoracotomy, guided by light of bronchoscope
- Lung biopsies through above incisions, unguided


El-Ebiary M et al. Am J Resp Crit Care Med 1997;156:583













e				
orest	i loli	Candida spp.	No Candida	
Y	AV .	(n = 82)	spp. (n = 303)	р
C	tients with NV-ICUAP that needed subsequent intubation, n (%)	27 (79)	71 (57)	0.018
	CU stay, days	21±16	22±20	0.79
G H	lospital stay, days	44±28	43±36	0.99
lr	appropriate empiric treatment, n (%)	10 (26)	38 (18)	0.24
N	lon-response to treatment, n (%)	48 (59)	167 (55)	0.58
V	entilator-free days at day 28 ^a	12 (0-24)	7 (0-23)	0.50





RCT: antifungal for VAP with Candida in ETT								
		Placebo	Antifungal	р	Observational			
C O	n	29	31		29			
	APACHE	23	22		20.9			
	Baseline SOFA	38	38		38			
	ICU LOS	11.5	13	0.35	11			
	Hospital LOS	29	28	0.9	29.5			
	28-day mortality	6 (20.7%)	7 (22.6%)	0.86	5 (17.2%)			
	90-day mortality	7 (24.1%)	10 (32.3%)	0.49	6 (20.7%)			

